In:
COSMOS, World Scientific Pub Co Pte Ltd, Vol. 08, No. 01 ( 2012-06), p. 121-134
Abstract:
The serendipitous discovery of the antitumor properties of cisplatin by Barnett Rosenberg some forty years ago brought about a paradigm shift in the field of medicinal chemistry and challenged conventional thinking regarding the role of potentially toxic heavy metals in drugs. Platinum(II)-based anticancer drugs have since become some of the most effective and widely-used drugs in a clinician's arsenal and have saved countless lives. However, they are limited by high toxicity, severe side-effects and the incidence of drug resistance. In recent years, attention has shifted to stable platinum(IV) complexes as anticancer prodrugs. By exploiting the unique chemical and structural attributes of their scaffolds, these platinum(IV) prodrugs offer new strategies of targeting and killing cancer cells. This review summarizes the development of anticancer platinum(IV) prodrugs to date and some of the exciting strategies that utilise the platinum(IV) construct as targeted chemotherapeutic agents against cancer.
Type of Medium:
Online Resource
ISSN:
0219-6077
,
1793-7051
DOI:
10.1142/S0219607712300020
Language:
English
Publisher:
World Scientific Pub Co Pte Ltd
Publication Date:
2012
Permalink